ENG
Retinal Vasculitis Treatment Market: Global Industry Analysis and Forecast (2023-2029) by Drug Type, Infection Type, Distribution Channel, and Region
Retinal Vasculitis Treatment Market size was valued at US$ 10.73 Billion in 2022 and the Retinal Vasculitis Treatment revenue is expected to grow at 8% through 2023 to 2029, reaching nearly US$ 18.39 Billion
Format : PDF | Report ID : SMR_363
Retinal Vasculitis Treatment Market Definition & Overview:
Retinal Vasculitis is a condition in which the blood vessels in the ocular area become inflamed as a result of other ailments such as autoimmunity, inflammatory disorders, infectious diseases, and neoplastic diseases. According to CDC and Statistics figures, the prevalence of this inflammatory disorder is rising every day. This will have a direct impact on research and development in terms of developing effective treatments and, as a result, retinal vasculitis treatment market growth.
Retinal Vasculitis Treatment Market Dynamics:
The key driver of the retinal vasculitis treatment market is the use of Aflibercept injections to treat rare syndromes like IRVAN (Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis). Another important factor boosting the market for retinal vasculitis treatment is the increased frequency of inflammatory illnesses. Advanced treatments like as fluorescein angiography and swept source-ocular coherence tomography angiography (ss-OCTA) help to drive the market forward. Additionally, the market is being propelled ahead by increased research and development for controlling and enhancing retinal vasculitis.
The use of intravitreal Aflibercept injections in the treatment of retinal vasculitis is the primary factor driving demand for this treatment market. These injections help to reduce edema at the location of the inflammation. The utility of these injections in the treatment of a rare illness known as IRVAN (Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis) syndrome was confirmed in a study published in PubMed in February 2020. This condition includes retinal vasculitis. The use of Fluorescein Angiography (FA) in the identification of retinal vasculitis in children with Paediatric Uveitis at Children's Medical Center in Dallas was investigated in a study published in Ophthalmology Retina. FA has become another key driving force in the retinal vasculitis treatment market as a result of the findings of this study.
Retinal Vasculitis Treatment Market Segment Analysis:
By Distribution Channel, In terms of revenue, the retail pharmacies segment dominated the retinal condition treatment market in 2020. During the forecast period, the tendency is likely to continue. Due to its extensive network, ease of access, and broad product offers, which include both prescription and over-the-counter ophthalmic medications, retail pharmacies led the global retinal vasculitis treatment market. During the forecast period, online sales are expected to be a significant area of the global market. From 2020 to 2027, the category is expected to grow at a considerable CAGR. During the forecast period, the changing tilt toward the usage of electronic payment options is expected to result in a high market share for the online sales segment.
Retinal Vasculitis Treatment Market Regional Insights:
According to the Centers for Disease Control and Prevention (CDC), 4.2 million Americans have an ocular disease, showing that the frequency of retinal illnesses is increasing in the United States. A new set of ophthalmic therapies about to be released in the nation will help to push the market in the right direction. Authorities in this country are now placing a greater emphasis on R&D spending in order to better the management and treatment of retinal illnesses. As a result of these factors, the United States is a market leader in the treatment of retinal vasculitis in the North American region. According to recent statistics, over 11 million people in the United States suffer from age-related macular degeneration, with that figure anticipated to quadruple to over 22 million by 2050.
According to data provided by Statista, 3.6 percent of eastern Europeans suffer from some form of vision impairment as of 2020. As a result, there is a growing demand for improved and rapid treatment of retinal problems. Additionally, throughout the forecast period, rising technical progress and increased investment in R&D are likely to boost retinal vasculitis treatment market growth.
The objective of the report is to present a comprehensive analysis of the Retinal Vasculitis Treatment Market to the stakeholders in the industry. The report provides trends that are most dominant in the Retinal Vasculitis Treatment Market and how these trends will influence new Business investments and market development throughout the forecast period. The report also aids in the comprehension of the market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.
The qualitative and quantitative data provided in the Retinal Vasculitis Treatment Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Retinal Vasculitis TreatmentMarket. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the Retinal Vasculitis TreatmentMarket.
The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Retinal Vasculitis Treatment Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.
Retinal Vasculitis Treatment Market Scope:
|
Retinal Vasculitis Treatment Market Scope |
|
|
Market Size in 2022 |
USD 10.73 Bn. |
|
Market Size in 2029 |
USD 18.39 Bn. |
|
CAGR (2023-2029) |
8% |
|
Historic Data |
2017-2021 |
|
Base Year |
2022 |
|
Forecast Period |
2023-2029 |
|
Segment Scope |
by Drug Type
|
|
by Infection Type
|
|
|
by Distribution channel
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Retinal Vasculitis Treatment Market Players:
- Regeneron Pharmaceuticals, Inc. (United States)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Shire (Takeda Pharmaceutical Company Limited) (Japan)
- Bayer AG (Germany)
- Santen Pharmaceutical Co., Ltd. (Japan)
- Pfizer, Inc. (United States)
- Allergan plc (Ireland)
- Graybug Vision, Inc. (United States)
- Novartis AG (Switzerland)
- Acucela Inc. (Seattle, WA)
- Merck & Co., Inc. (United States)
Frequently Asked Questions
important factor boosting the market for retinal vasculitis treatment is the increased frequency of inflammatory illnesses.
North America accounted for the largest share of the Retinal Vasculitis Treatment Market.
According to data provided by Statista, 3.6 percent of eastern Europeans suffer from some form of vision impairment as of 2020. As a result, there is a growing demand for improved and rapid treatment of retinal problems.
Regeneron Pharmaceuticals, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Shire (Takeda Pharmaceutical Company Limited) (Japan), and Bayer AG (Germany).
Chapter 1 Scope of the Report
Chapter 2 Research Methodology
2.1. Research Process
2.2. Global Retinal Vasculitis Treatment Market: Target Audience
2.3. Global Retinal Vasculitis Treatment Market: Primary Research (As per Client Requirement)
2.4. Global Retinal Vasculitis Treatment Market: Secondary Research
Chapter 3 Executive Summary
Chapter 4 Competitive Landscape
4.1. Market Share Analysis, By Region, 2022-2029(In %)
4.1.1.1. North America Market Share Analysis, By Value, 2022-2029 (In %)
4.1.1.2. Europe Market Share Analysis, By Value, 2022-2029 (In %)
4.1.1.3. Asia Pacific Market Share Analysis, By Value, 2022-2029 (In %)
4.1.1.4. South America Market Share Analysis, By Value, 2022-2029 (In %)
4.1.1.5. Middle East and Africa Market Share Analysis, By Value, 2022-2029 (In %)
4.2. Market Dynamics
4.2.1. Market Drivers
4.2.2. Market Restraints
4.2.3. Market Opportunities
4.2.4. Market Challenges
4.2.5. PESTLE Analysis
4.2.6. PORTERS Five Force Analysis
4.2.7. Value Chain Analysis
4.3. Global Retinal Vasculitis Treatment Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.3.1.1. Global Market Share Analysis, By Drug Type, 2022-2029 (Value US$ MN)
4.3.1.1.1. Corticosteroids
4.3.1.1.2. Anti-Inflammatory
4.3.1.1.3. Immunosuppressants
4.3.1.2. Global Market Share Analysis, By Infection Type, 2022-2029 (Value US$ MN)
4.3.1.2.1. Bacterial
4.3.1.2.2. Viral
4.3.1.2.3. Fungal
4.3.1.2.4. Parasitic
4.3.1.2.5. Rickettsia
4.3.1.3. Global Market Share Analysis, By Distribution channel, 2022-2029 (Value US$ MN)
4.3.1.3.1. Hospital Pharmacies
4.3.1.3.2. Retail Stores Pharmacies
4.3.1.3.3. Online Stores
4.3.1.3.4. Others
4.4. North America Retinal Vasculitis Treatment Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.4.1.1. North America Market Share Analysis, By Drug Type, 2022-2029 (Value US$ MN)
4.4.1.1.1. Corticosteroids
4.4.1.1.2. Anti-Inflammatory
4.4.1.1.3. Immunosuppressants
4.4.1.2. North America Market Share Analysis, By Infection Type, 2022-2029 (Value US$ MN)
4.4.1.2.1. Bacterial
4.4.1.2.2. Viral
4.4.1.2.3. Fungal
4.4.1.2.4. Parasitic
4.4.1.2.5. Rickettsia
4.4.1.3. North America Market Share Analysis, By Distribution channel, 2022-2029 (Value US$ MN)
4.4.1.3.1. Hospital Pharmacies
4.4.1.3.2. Retail Stores Pharmacies
4.4.1.3.3. Online Stores
4.4.1.3.4. Others
4.4.1.4. North America Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.4.1.4.1. US
4.4.1.4.2. Canada
4.4.1.4.3. Mexico
4.5. Europe Retinal Vasculitis Treatment Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.5.1.1. Europe Market Share Analysis, By Drug Type, 2022-2029 (Value US$ MN)
4.5.1.2. Europe Market Share Analysis, By Infection Type, 2022-2029 (Value US$ MN)
4.5.1.3. Europe Market Share Analysis, By Distribution channel, 2022-2029 (Value US$ MN)
4.5.1.4. Europe Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.5.1.4.1. UK
4.5.1.4.2. France
4.5.1.4.3. Germany
4.5.1.4.4. Italy
4.5.1.4.5. Spain
4.5.1.4.6. Sweden
4.5.1.4.7. Austria
4.5.1.4.8. Rest Of Europe
4.6. Asia Pacific Retinal Vasculitis Treatment Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.6.1.1. Asia Pacific Market Share Analysis, By Drug Type, 2022-2029 (Value US$ MN)
4.6.1.2. Asia Pacific Market Share Analysis, By Infection Type, 2022-2029 (Value US$ MN)
4.6.1.3. Asia Pacific Market Share Analysis, By Distribution channel, 2022-2029 (Value US$ MN)
4.6.1.4. Asia Pacific Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.6.1.4.1. China
4.6.1.4.2. India
4.6.1.4.3. Japan
4.6.1.4.4. South Korea
4.6.1.4.5. Australia
4.6.1.4.6. ASEAN
4.6.1.4.7. Rest Of APAC
4.7. South America Retinal Vasculitis Treatment Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.7.1.1. South America Market Share Analysis, By Drug Type, 2022-2029 (Value US$ MN)
4.7.1.2. South America Market Share Analysis, By Infection Type, 2022-2029 (Value US$ MN)
4.7.1.3. South America Market Share Analysis, By Distribution channel, 2022-2029 (Value US$ MN)
4.7.1.4. South America Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.7.1.4.1. Brazil
4.7.1.4.2. Argentina
4.7.1.4.3. Rest Of South America
4.8. Middle East and Africa Retinal Vasculitis Treatment Market Segmentation Analysis, 2022-2029 (Value US$ MN)
4.8.1.1. Middle East and Africa Market Share Analysis, By Drug Type, 2022-2029 (Value US$ MN)
4.8.1.2. Middle East and Africa Market Share Analysis, By Infection Type, 2022-2029 (Value US$ MN)
4.8.1.3. Middle East and Africa Market Share Analysis, By Distribution channel, 2022-2029 (Value US$ MN)
4.8.1.4. Middle East and Africa Market Share Analysis, By Country, 2022-2029 (Value US$ MN)
4.8.1.4.1. South Africa
4.8.1.4.2. GCC
4.8.1.4.3. Egypt
4.8.1.4.4. Nigeria
4.8.1.4.5. Rest Of ME&A
Chapter 5 Stellar Competition Matrix
5.1.1. Global Stellar Competition Matrix
5.1.2. North America Stellar Competition Matrix
5.1.3. Europe Stellar Competition Matrix
5.1.4. Asia Pacific Stellar Competition Matrix
5.1.5. South America Stellar Competition Matrix
5.1.6. Middle East and Africa Stellar Competition Matrix
5.2. Key Players Benchmarking
5.2.1. Key Players Benchmarking By Application, Pricing, Market Share, Investments, Expansion Plans, Physical Presence and Presence in the Market.
5.3. Mergers and Acquisitions in Industry
5.3.1. M&A by Region, Value and Strategic Intent
Chapter 6 Company Profiles
6.1. Key Players
6.1.1. F. Hoffmann-La Roche Ltd.
6.1.1.1. Company Overview
6.1.1.2. Source Portfolio
6.1.1.3. Financial Overview
6.1.1.4. Business Strategy
6.1.1.5. Key Developments
6.1.2. Regeneron Pharmaceuticals, Inc.
6.1.3. F. Hoffmann-La Roche Ltd.
6.1.4. Shire (Takeda Pharmaceutical Company Limited)
6.1.5. Bayer AG
6.1.6. Santen Pharmaceutical Co., Ltd.
6.1.7. Pfizer, Inc.
6.1.8. Allergan plc
6.1.9. Graybug Vision, Inc.
6.1.10. Novartis AG
6.1.11. Acucela Inc. (Seattle, WA)
6.1.12. Merck & Co., Inc. (United States)
6.2. Key Findings
6.3. Recommendations
